8 results
8-K
EX-99.1
MRVI
Maravai LifeSciences Holdings Inc - Ordinary Shares
7 Nov 23
Maravai Lifesciences Reports Third Quarter 2023 Financial Results
4:11pm
period in the prior year as customers continued to focus on capital conservation efforts.
Biologics Safety Testing revenue was $15.6 million … .
Given the current market conditions, including prolonged customer capital conservation efforts, total revenue for 2023 is now projected
8-K
EX-99.1
MRVI
Maravai LifeSciences Holdings Inc - Ordinary Shares
22 Feb 24
Maravai Lifesciences Reports Fourth Quarter and Full Year 2023 Financial Results
4:08pm
challenging industry conditions, customers continuing to focus on capital conservation and heightened competition in certain areas.
Biologics Safety
S-1/A
EX-10.26
MRVI
Maravai LifeSciences Holdings Inc - Ordinary Shares
9 Nov 20
IPO registration (amended)
2:05pm
promulgated, enacted, adopted or amended, relating to (i) safety (including occupational health and safety); (ii) pollution, conservation
S-1
EX-10.18
MRVI
Maravai LifeSciences Holdings Inc - Ordinary Shares
29 Oct 20
IPO registration
5:04pm
guidelines or controls imposed upon either Landlord or Tenant by any Governmental Authority or by any energy conservation association to which Landlord … Conservation and Recovery Act, as amended (42 U.S.C. Section 6901 et seq.), and California Health and Safety Code (Sections 25100, 25249.5, 25316
DRS/A
EX-10.18
msyaopcufzgafbfu
14 Oct 20
Draft registration statement (amended)
12:00am
DRS/A
EX-10.17
w5px8x6nboa5h 6h
14 Oct 20
Draft registration statement (amended)
12:00am
S-1
EX-10.17
ul3mt4x9evdzg0mx
29 Oct 20
IPO registration
5:04pm
- Prev
- 1
- Next